474 related articles for article (PubMed ID: 7545084)
21. Studies on the order and site specificity of GalNAc transfer to MUC1 tandem repeats by UDP-GalNAc: polypeptide N-acetylgalactosaminyltransferase from milk or mammary carcinoma cells.
Stadie TR; Chai W; Lawson AM; Byfield PG; Hanisch FG
Eur J Biochem; 1995 Apr; 229(1):140-7. PubMed ID: 7744025
[TBL] [Abstract][Full Text] [Related]
22. Coexpression of MUC1 mucin peptide core and the Thomsen-Friedenreich antigen in colorectal neoplasms.
Baldus SE; Hanisch FG; Kotlarek GM; Zirbes TK; Thiele J; Isenberg J; Karsten UR; Devine PL; Dienes HP
Cancer; 1998 Mar; 82(6):1019-27. PubMed ID: 9506345
[TBL] [Abstract][Full Text] [Related]
23. T cells recognize PD(N/T)R motif common in a variable number of tandem repeat and degenerate repeat sequences of MUC1.
Pisarev VM; Kinarsky L; Caffrey T; Hanisch FG; Sanderson S; Hollingsworth MA; Sherman S
Int Immunopharmacol; 2005 Feb; 5(2):315-30. PubMed ID: 15652762
[TBL] [Abstract][Full Text] [Related]
24. An efficient approach for the characterization of mucin-type glycopeptides: the effect of O-glycosylation on the conformation of synthetic mucin peptides.
Hashimoto R; Fujitani N; Takegawa Y; Kurogochi M; Matsushita T; Naruchi K; Ohyabu N; Hinou H; Gao XD; Manri N; Satake H; Kaneko A; Sakamoto T; Nishimura S
Chemistry; 2011 Feb; 17(8):2393-404. PubMed ID: 21264968
[TBL] [Abstract][Full Text] [Related]
25. Second generation anti-MUC1 peptide monoclonal antibodies.
Xing PX; Prenzoska J; Quelch K; McKenzie IF
Cancer Res; 1992 Apr; 52(8):2310-7. PubMed ID: 1373108
[TBL] [Abstract][Full Text] [Related]
26. Chemoenzymatically synthesized multimeric Tn/STn MUC1 glycopeptides elicit cancer-specific anti-MUC1 antibody responses and override tolerance.
Sørensen AL; Reis CA; Tarp MA; Mandel U; Ramachandran K; Sankaranarayanan V; Schwientek T; Graham R; Taylor-Papadimitriou J; Hollingsworth MA; Burchell J; Clausen H
Glycobiology; 2006 Feb; 16(2):96-107. PubMed ID: 16207894
[TBL] [Abstract][Full Text] [Related]
27. Access to peptide regions of a surface mucin (MUC1) is reduced by sialic acids.
Ho JJ; Cheng S; Kim YS
Biochem Biophys Res Commun; 1995 May; 210(3):866-73. PubMed ID: 7539263
[TBL] [Abstract][Full Text] [Related]
28. Biomimetic synthesis of the tumor-associated (2,3)-sialyl-T antigen and its incorporation into glycopeptide antigens from the mucins MUC1 and MUC4.
Dziadek S; Brocke C; Kunz H
Chemistry; 2004 Sep; 10(17):4150-62. PubMed ID: 15352098
[TBL] [Abstract][Full Text] [Related]
29. Humoral immunity against a tandem repeat epitope of human mucin MUC-1 in sera from breast, pancreatic, and colon cancer patients.
Kotera Y; Fontenot JD; Pecher G; Metzgar RS; Finn OJ
Cancer Res; 1994 Jun; 54(11):2856-60. PubMed ID: 7514493
[TBL] [Abstract][Full Text] [Related]
30. Preparation and characterization of monoclonal antibodies directed to the tumor-associated O-linked sialosyl-2----6 alpha-N-acetylgalactosaminyl (sialosyl-Tn) epitope.
Kjeldsen T; Clausen H; Hirohashi S; Ogawa T; Iijima H; Hakomori S
Cancer Res; 1988 Apr; 48(8):2214-20. PubMed ID: 2450649
[TBL] [Abstract][Full Text] [Related]
31. Expression of the Thomsen-Friedenreich antigen and of its putative carrier protein mucin 1 in the human placenta and in trophoblast cells in vitro.
Jeschke U; Richter DU; Hammer A; Briese V; Friese K; Karsten U
Histochem Cell Biol; 2002 Mar; 117(3):219-26. PubMed ID: 11914919
[TBL] [Abstract][Full Text] [Related]
32. Conformational studies on the MUC1 tandem repeat glycopeptides: implication for the enzymatic O-glycosylation of the mucin protein core.
Kinarsky L; Suryanarayanan G; Prakash O; Paulsen H; Clausen H; Hanisch FG; Hollingsworth MA; Sherman S
Glycobiology; 2003 Dec; 13(12):929-39. PubMed ID: 12925576
[TBL] [Abstract][Full Text] [Related]
33. Oligosaccharide differences in the DF3 sialomucin antigen from normal human milk and the BT-20 human breast carcinoma cell line.
Hull SR; Bright A; Carraway KL; Abe M; Hayes DF; Kufe DW
Cancer Commun; 1989; 1(4):261-7. PubMed ID: 2639730
[TBL] [Abstract][Full Text] [Related]
34. Epitope mapping of antigenic MUC1 peptides to breast cancer antibody fragment B27.29: a heteronuclear NMR study.
Grinstead JS; Schuman JT; Campbell AP
Biochemistry; 2003 Dec; 42(48):14293-305. PubMed ID: 14640698
[TBL] [Abstract][Full Text] [Related]
35. The epitope recognized by the unique anti-MUC1 monoclonal antibody MY.1E12 involves sialyl alpha 2-3galactosyl beta 1-3N-acetylgalactosaminide linked to a distinct threonine residue in the MUC1 tandem repeat.
Takeuchi H; Kato K; Denda-Nagai K; Hanisch FG; Clausen H; Irimura T
J Immunol Methods; 2002 Dec; 270(2):199-209. PubMed ID: 12379325
[TBL] [Abstract][Full Text] [Related]
36. Human single-chain Fv antibodies to MUC1 core peptide selected from phage display libraries recognize unique epitopes and predominantly bind adenocarcinoma.
Henderikx P; Kandilogiannaki M; Petrarca C; von Mensdorff-Pouilly S; Hilgers JH; Krambovitis E; Arends JW; Hoogenboom HR
Cancer Res; 1998 Oct; 58(19):4324-32. PubMed ID: 9766660
[TBL] [Abstract][Full Text] [Related]
37. Specificity clusters of MUC1-reactive mouse monoclonal antibodies.
Hanisch FG
Tumour Biol; 1998; 19 Suppl 1():111-7. PubMed ID: 9422095
[TBL] [Abstract][Full Text] [Related]
38. Human colon adenocarcinomas express a MUC1-associated novel carbohydrate epitope on core mucin glycans defined by a monoclonal antibody (A10) raised against murine Ehrlich tumor cells.
Medina M; Vélez D; Asenjo JA; Egea G; Real FX; Gil J; Subiza JL
Cancer Res; 1999 Mar; 59(5):1061-70. PubMed ID: 10070964
[TBL] [Abstract][Full Text] [Related]
39. Design of a MUC1-based cancer vaccine.
Hanisch FG
Biochem Soc Trans; 2005 Aug; 33(Pt 4):705-8. PubMed ID: 16042579
[TBL] [Abstract][Full Text] [Related]
40. Site-specific conformational alteration induced by sialylation of MUC1 tandem repeating glycopeptides at an epitope region for the anti-KL-6 monoclonal antibody.
Matsushita T; Ohyabu N; Fujitani N; Naruchi K; Shimizu H; Hinou H; Nishimura S
Biochemistry; 2013 Jan; 52(2):402-14. PubMed ID: 23259747
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
